Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma.

Study Overview
=================
Brief Summary
-----------------
In the present study, we have trained 10 patients in subcutaneous self-administration of Velcade. After their training, patients will alternately receive their treatment in the hospital and at home by self-administration. In keeping with common practice, a nurse contacts the patients by telephone before 9.00 am on the day of treatment to ensure that the patient is physically fit to receive the medication and to discuss any side effects. To highlight the advantages and disadvantages of the changed treatment practice from the perspectives of both patients and healthcare professionals, data is collected from two consecutive semi-structured interviews with n = 10 patients and n = 1 focus group interview of the healthcare professionals involved. Moreover, time registration of medication administration both at the hospital and in the patients' home is done. The qualitative data will be analyzed via the method of condensation and continual quantitative data will form the basis of a cost-benefit analysis.

Official Title
-----------------
Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma.

Conditions
-----------------
Multiple Myeloma

Intervention / Treatment
-----------------
* Drug: Bortezomib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria Patients must have Multiple Myeloma Patients (or their relatives) must be deemed physically and cognitively suitable and willing for self-administration of subcutaneous Velcade Patients must be able to understand and speak Danish Patients must have received a minimum of 1 treatment cycle in the outpatient clinic Exclusion criteria Lack of willingness to participate in scheduled interviews Patients who are cognitively affected Must not be receiving trial treatment
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Bortezomib|Self-administration of subcutaneously Velcade.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patients experience of self-administration of Velcade | Qualitative interviews with all 10 included patients | Through study completion, from 01. dec. 2019 until 01. jun. 2022 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Organizational perspective | Patients and health professionals (including pharmacy staff) registration of time spend on treatment on all 10 included patients. | Through study completion, from 01. dec. 2019 until 01. jun. 2022 | 
| Health care perspective | Focus group interview with healthcare professionals involved in the treatment. | Through study completion, from 01. dec. 2019 until 01. jun. 2022 | 
| Financial perspective | Evaluation of financial savings on home treatment including healthcare salaries and transportation. | Through study completion, from 01. dec. 2019 until 01. jun. 2022 |